Asia Spotlight: Nike’s Importation Fine Serves As A Lesson For Drug Firms In China
Beijing issued Nike a RMB 4.87 million fine for using double standards for an imported product in China, prompting legal and industry watchers to warn multinational companies to keep prices competitive or they could find themselves under tighter scrutiny.
You may also be interested in...
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.
A former pharma executive shares views with Scrip about the coronavirus in China, the challenges facing corporations and individuals in a rapidly changing world and coming threats that could potentially cause even more damage than the pandemic.
Leveraging its Ebola vaccine success, Tianjin-based CanSino is looking to launch China’s first vaccine for COVID-19 as it secures permission to start local clinical trials.